GHRP-6

Status

No approved product. No FDA-approved labeling exists. Not an approved medicine in the United States.

What it is

An early GH releasing peptide known in studies for marked hunger.

What published research measured

One of the earliest synthetic growth hormone secretagogues, a hexapeptide acting at the ghrelin receptor. Human studies from the 1990s onward established that it releases growth hormone and, more distinctively, that it produces pronounced hunger — it is a ghrelin mimetic and appetite stimulation is a direct consequence of the mechanism rather than a side effect. Like the related hexapeptides it is reported to raise prolactin and cortisol somewhat. No trial evidence supports use for muscle gain or fat loss in healthy adults; the human literature is pharmacology and diagnostics, not outcomes.

Source

Frontiers in Endocrinology 2026 review — GH secretagogues and the GH–IGF-1 axis

Sources

• Primary source
• Primary source
• CDC handling principles